Invesco Physical Markets Public Limited Company listed a new physical gold exchange-traded product (ETP) on SIX Swiss Exchange, on 27th August, 2021. Lenz & Staehelin assisted Invesco with all Swiss regulatory aspects for the listing
The Deutsche Börse Group, an international exchange organisation and innovative market infrastructure provider, acquires a majority of the shares in Crypto Finance, a Swiss crypto broker and asset manager. Through the acquisition, Deutsche Bö
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Walder Wyss has acted as advisor to Sleepiz in the completion of its CHF 4.4 million Series A financing round. The newly raised capital will support Sleepiz expansion of its portfolio to chronic respiratory disease monitoring.
Norres, a portfolio company of Triton Smaller Mid-Cap Fund I, acquired the Baggerman Group. The parties have agreed not to disclose the purchase price. The Baggerman Group, headquartered in Roermond, Netherlands, is a specialist
CMS Switzerland welcomed Vaïk Müller (pictured) as a partner of the firm. In his new role, Müller will help develop the firm’s expertise in areas of banking & finance along with
Gxo Logistics, a global provider of transportation and logistics solutions, has appointed Maria Elena Scolaro (pictured) as head of legal affairs for Italy and Switzerland. Scolaro is reporting to general counsel for Europe and to
The city of Sierre, the association of the municipalities of the District of Sierre and TechnoArk acquired a majority stake in the Techno-Pôle of Sierre. Python acted as counsel to the buyers. Python team
Maus Frères and Coop-Group cooperative announced the sale of all shares of Jumbo-Markt, a Swiss do-it-yourself store operator, for an undisclosed consideration. Following merger control clearance by the Swiss Competition Commission the transaction has
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
